Navigation Links
Onyx Pharmaceuticals to Present at the Credit Suisse 18th Annual Healthcare Conference
Date:11/4/2009

EMERYVILLE, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will present at the Credit Suisse 18th Annual Healthcare Conference on Wednesday, November 11, at 9:30 a.m. Mountain Time (8:30 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available one hour following the conclusion of the presentation through December 11, 2009.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

SOURCE Onyx Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
3. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
4. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
5. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
6. Transdel Pharmaceuticals to Present at Two Investor Conferences
7. Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy
8. Amylin Pharmaceuticals to Webcast Third Quarter Results
9. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
10. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
11. United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStems Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... Michael Zasloff , MD, Ph.D., Professor ... Medicine, and Founder, Chairman and CEO of Enterin Inc. ... helped clarify the function of alpha-Synuclein (aS), the protein ... Denise Barbut , MD, FRCP, Co-Founder, President and ... of the study. Published in the Journal ...
(Date:6/28/2017)... , ... June 28, 2017 , ... ... Bock UK Ltd (Bock) announced a strategic partnership where Bock will ... enzyme technology, OPTIMASH® AD-100, has been shown to help biogas producers in the ...
(Date:6/28/2017)... ... June 28, 2017 , ... Studies indicate that replacing damaged brain cells with ... Parkinson’s disease. But what has not been determined is the optimal stage during differentiation ... results. , A new study coming out of Singapore, recently published in STEM CELLS ...
(Date:6/27/2017)... , ... June 27, 2017 , ... Biodex Medical Systems, ... ambulation aid in one device. This assistive aid lifts patients safely from a seated ... and motorized lift mechanics. The Mobility Assist is the latest in a line of ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 Forecasts ... ANPR, Document Readers, by End-Use (Transportation & Logistics, Government ... Oil, Gas & Fossil Generation Facility, Nuclear Power), Industrial, ... Other) Are you looking for a definitive ... ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):